Antimicrobial peptides (AMPs) are effector molecules of innate immunity. Dermcidin (DCD), a recently discovered AMP with broad-spectrum activity, is produced constitutively by the eccrine sweat glands and secreted into sweat. In this study, we investigated the proteolytic processing, site-specific expression, and stability of DCD peptides in eccrine sweat. Using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and reversed-phase high-pressure liquid chromatography analysis, we identified in eccrine sweat 14 proteolytically processed DCD peptides. Semiquantitative SELDI-TOF-MS analysis indicated that processing of DCD-1L is individually different, but generates a few dominant peptides. At body sites with a high probability for contact with pathogenic microorganisms, a high amount of antimicrobial active DCD peptides was detected in sweat. Furthermore, we show that the secretion rate of DCD is constant during a period of prolonged sweating and that DCD peptides are stable in sweat over several hours. Other known AMPs like the human cathelicidin LL-37 and a-or b-defensins were not detected in significant quantity in eccrine sweat. Owing to the durable and abundant presence, DCD-derived peptides contribute to the first line of defense by building a constant barrier that overlies the epithelial skin.
INTRODUCTION
Epithelia of multicellular organisms are continuously exposed to a large number of microorganisms. The remarkable resistance to infection indicates effective defense mechanisms along the epithelial barriers. Within this first line of defense, antimicrobial peptides (AMPs) are emerging as important effector molecules.
In mammalian skin, AMPs are produced by cells within the epithelial lining, are delivered by circulating cells, or are produced by adjacent cells of the epithelial appendages. In human skin, keratinocytes are a major source of antimicrobial active peptides or larger proteins. Whereas the ribonuclease RNase 7 (Harder and Schroder, 2002) , psoriasin (S100A7) (Glaser et al., 2005) , and secretory leukoprotease inhibitor (Wiedow et al., 1998) are produced constitutively by keratinocytes, the human cathelicidin LL-37 (Frohm et al., 1997) and the b-defensin-2 (HBD-2) and -3 (HBD-3) (Harder et al., 1997 (Harder et al., , 2001 are induced in keratinocytes under inflammatory conditions.
We recently discovered a new AMP named dermcidin (DCD) with a broad spectrum of activity and no homology to other known AMPs (Schittek et al., 2001) . DCD is expressed in the eccrine sweat glands, secreted into sweat, and transported via sweat to the epidermal surface. In contrast to other AMPs such as human cathelicidin LL-37 and the human b-defensins, DCD is not induced in epidermal keratinocytes under inflammatory skin conditions like atopic dermatitis, psoriasis, or lichen planus, but is constitutively produced by the eccrine sweat glands (Rieg et al., 2004) . Thus, DCD takes part in the constitutive innate defense of human skin. Recently, we showed that patients with atopic dermatitis have a reduced amount of DCD peptides in sweat, which correlated with diminished antimicrobial activity of eccrine sweat in vivo .
Analogous to other known AMPs, a precursor protein of DCD is produced, which is proteolytically processed to generate antimicrobial active DCD peptides. The DCDprecursor protein consists of 110-amino-acid residues with a 19-amino-acid N-terminal signal peptide (Schittek et al., 2001) . Antimicrobial active DCD peptides are derived from the C-terminal region of the precursor protein, DCD-1L (consisting of 48 amino acids) and DCD-1 (47 amino acids, lacking the last leucine). Both peptides show antimicrobial activity against a variety of pathogenic microorganisms including Staphylococcus aureus, E. coli, Entercoccus faecalis, and Candida albicans under in vitro conditions resembling human sweat. In human sweat, 1-10 mg/ml of DCD-1 is found, a concentration that is toxic to most microorganisms tested (Schittek et al., 2001; Flad et al., 2002) . Using surfaceenhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology, we described that besides these peptides, shorter peptides with 43-46 amino acids could be identified in eccrine sweat (Flad et al., 2002) .
In this study, we investigated (a) the spectrum of proteolytically processed DCD peptides and (b) the presence of other AMPs like human defensins and the human cathelicidin LL-37 in eccrine sweat of healthy volunteers using reversed-phase high-pressure liquid chromatography (RP-HPLC) and SELDI-TOF-MS. Furthermore, we analyzed whether (a) the amount of DCD peptides in sweat differs between several body sites, (b) the rate of DCD secretion remains constant over time, (c) whether DCD peptides are stable in sweat, and (d) whether DCD-derived peptides are present in tears, saliva, and nasal secretions.
RESULTS

Several DCD-derived peptides are present in human sweat
Using SELDI-TOF-MS, we previously identified in human sweat from healthy persons five proteolytically processed peptides derived from the full-length DCD protein sequence (Schittek et al., 2001; Flad et al., 2002) . Among those are the peptides DCD-1L (48mer) and DCD-1 (47mer), which are antimicrobially active on different microorganisms.
To get the spectrum of all possible processed DCD peptides in sweat, we performed SELDI-TOF-MS analysis of physical-exercise-induced sweat of the forehead of 18 healthy volunteers (Figure 1 ). In addition, we separated sweat of four healthy volunteers by RP-HPLC and performed from the collected fractions mass spectrometry and Edman sequencing as described earlier (Figure 2) (Schittek et al., 2001) . In Table 1 , all identified processed DCD-derived peptides are summarized. We identified 13 different DCD peptides derived from the C-terminal end and one N-terminal-derived peptide named YDP-42 and its dimeric form. DCD-1 (pos. 63-109) and SSL-46 have lost the last leucine or valine residue, respectively, compared to the parental peptide DCD-1L and SSL-45 has in addition lost the serine. SSL-29 and SSL-25 are shorter peptides and have the same N-terminus as DCD-1L, beginning with SSL. The other peptides lack the first three amino acids SSL from DCD-1L, beginning with the amino acids LEK, and are either 41-45 amino acids long (LEK-41 and LEK-45) or only 24 or 26 amino acids long . Interestingly, nine of the 13 C-terminal-derived DCD peptides are anionic, two peptides have a neutral charge and two shorter peptides -SSL-25 and LEK-24 -are cationic.
LL-37 and defensins are not expressed in significant quantity in eccrine sweat
It has been described that the AMP LL-37 and truncated forms of this peptide are present in sweat (Murakami et al., 2002 (Murakami et al., , 2004 . To analyze whether LL-37 and other known AMPs or proteins like a-and b-defensins and lysozyme are present in sweat, we performed SELDI-TOF-MS from sweat samples from 18 healthy volunteers and in parallel separated eccrine sweat by RP-HPLC and performed antimicrobial assays from the fractions. From antimicrobial active and nonactive fractions, we performed mass spectrometry and Edman sequencing. Using both methods besides DCD peptides, we could not detect other known AMPs in sweat in significant quantity (Figures 1 and 2) . Neither LL-37 (4,493.3 Da) nor the derivatives KR-20 (2,468.9 Da), RK-31 (3,800.5 Da), and 644.3 Da) as well as the b-defensins HBD-1 (3,928.6 Da), HBD-2 (4,328.2 Da), HBD-3 (5,155.2 Da), or a-defensins HNP-1 (3,442.1 Da), HNP-2 (3,371.0 Da), and HNP-3 (3,486.1 Da) are present in eccrine sweat. As the above-mentioned cathelicidins and defensins are cationic peptides, we carried out additional SELDI-TOF-MS analysis with a cation exchange chip (WCX2). In accordance with measurements with a reversed-phase chip (H4), none of the above-mentioned cationic AMPs could be detected ( Figure  3a) . Furthermore, to rule out a weak affinity of human cathelicidin, a-or b-defensins to the reversed-phase chip, we analyzed synthetic LL-37, HNP-2, and HBD-1 peptides on a reversed-phase chip. Synthetic LL-37 could be identified when added to eccrine sweat samples that did not contain LL-37-corresponding masses in previous analyses in concentrations as low as 2 mM (Figure 3b ). In SELDI analyses of sweat with low amounts of DCD-derived peaks in the molecular weight range of 4,493 Da, LL-37 can still be detected in a concentration of 1.1 mM (Figure 3b) . Accordingly, HNP-1/-2 and HBD-1 were detected in concentrations of 2.9 and 2.5 mM, respectively ( Figure 3c ); HBD-2 was detected in a concentration of 2.3 mM (Figure 3d ). Furthermore, using Western blot analysis, the a-defensins HNP-1, HNP-2, and HNP-3, b-defensin HBD-2 or lysozyme could not be detected in eccrine sweat, whereas DCD was readily detectable (Figure 3e ). Considering the sensitivity of our Western blot analysis, we conclude that the defensins are either absent from eccrine sweat or present at concentrations lower than 2 mM. These results indicate that DCD-derived peptides are the predominant AMPs in sweat, and that neither defensins nor LL-37 are present in significant quantity, that is, antimicrobial active quantity, in sweat.
Processing of DCD-1L is individually different, but generates a few dominant peptides SELDI analysis of sweat of 18 healthy persons indicates an individual proteolytic pattern of DCD-derived peptides in sweat (Figure 1) as well as the proteolytic pattern. Whereas in most individuals (13 volunteers), seven to nine C-terminal-derived DCD peptides are present in sweat, in a few individuals (five persons) only four to five DCD-derived peptides could be identified in sweat. Irrespective of the number of total processed peptides, most individuals have two to four major DCD-processed peptides in sweat (Table 2 ). This indicates that each individual processes the DCD peptides differently, but that there are prominent peptides such as DCD-1L, DCD-1, SSL-46, SSL-29, SSL-25 and LEK-45 that are present in the majority of sweat samples analyzed.
The amount of DCD-derived peptides in sweat is dependent on the body site To analyze whether there are differences in the amount of DCD-derived peptides secreted into sweat at various body sites, we performed semiquantitative analysis of DCD peptides in the sweat of healthy subjects using SELDI-TOF-MS. Sweat samples collected from various body sites of five healthy volunteers were applied together with 100 fmol of bovine insulin (MW 5,733.6 Da) on a reversed-phase (H4) Protein Chip Array (Ciphergen Biosystems, Freemont, CA). The spectra were analyzed by Protein Chip Software 3.1 (Ciphergen Biosystems, Freemont, CA). After baseline subtraction, all spectra were normalized to the bovine insulin peak for semiquantification of the DCD-derived peptides. As can be seen in Figure 4 , the amount of DCD-derived peptides is different at the various body sites. Whereas at the thorax and legs relatively low levels of DCD peptides are present in eccrine sweat, on the face, arms, and especially in the palms, the amount of DCD peptides in sweat is high. In the region of the axilla, where in contrast to the other analyzed body sites sweat is secreted predominantly, but not exclusively by apocrine sweat glands, the amount of DCD peptides is also 2,000 3,000 4,000 5,000 6,000 2,000 3,000 4,000 5,000 6,000 Figure 1 . Spectra of SELDI-TOF-MS-analysis of human sweat of 10 healthy volunteers using a reversed-phase (H4) protein chip. These spectra are representative of the SELDI-TOF-MS analysis of overall 18 analyzed sweat samples. Shown are masses from 2,000 to 6,000 Da. After baseline subtraction, spectra were normalized to the bovine insulin peak (5,733.6 Da). From the masses, several DCD-derived peptides could be identified (summarized in Table 1 ). The deviation of the masses measured in the SELDI-TOF-MS analyses to the theoretical masses listed in Table 1 is around 71.5 Da in the mass ranges 3,000-5,000 Da and around 73 Da in the mass ranges 2,000-3,000 Da.
low (data not shown). This reflects the fact that DCD is only expressed in eccrine sweat glands and not in apocrine sweat glands (Schittek et al., 2001; Minami et al., 2004) . These results imply that at body sites with a high probability for a contact with pathogens (palms, face, arms), a pronounced amount of antimicrobial DCD peptides is secreted into sweat.
DCD is secreted into sweat at a constant rate
Next, we asked whether the secretion rate of DCD into sweat changes over time. Therefore, we collected sweat from five volunteers at different time points during a prolonged episode of sweating -immediately at the beginning and 20 and 40 minutes afterwards -and performed a semiquantification using SELDI-TOF-MS. Figure 5 shows that the amount of DCD-derived peptides in sweat does not appreciably change during a sweating period of 40 minutes. This indicates that the secretion rate of DCD keeps constant over time.
DCD-derived peptides are stable in sweat
Are DCD peptides rapidly destroyed by proteases in sweat or are they stable? To answer this question, we collected native sweat and kept it at room temperature up to 72 hours. Sweat samples were evaluated by Western blot using the monoclonal G-81 antibody, which recognizes all C-terminal-derived DCD peptides. After incubation of sweat for 24, 48, and up to 72 hours, C-terminal DCD peptides were still detected by Western blot (Figure 6a ). Moreover, SELDI-TOF-MS analysis of eccrine sweat after 4, 16, and 40 hours of incubation at room temperature revealed mass profiles still containing prominent DCD peaks after 16 and 40 hours of incubation, yet a slow but continuous shift towards the processed DCD peptides LEK-43, LEK-42, LEK-41, and SSL-29 can be observed ( Figure 6b ). These results indicate that DCD peptides in sweat are relatively stable.
DCD peptides are not present in nasal secretion, tears, and saliva
Next, we analyzed whether DCD-derived peptides are present in other body fluids like nasal secretions, tears, and saliva. As can be seen in Figure 7 , DCD peptides are not present in these body fluids, whereas the a-defensins HNP-1, HNP-2, and HNP-3 are present in saliva and to a lesser extent in tears. Other AMPs like b-defensins and LL-37 were not detected by SELDI-TOF-MS analysis in tears, nasal fluid, and saliva. As the sensitivity of the SELDI-TOF-MS method for the detection of b-defensins and LL-37 is in the range of 2 mM (see above), these peptides are either absent or present at concentrations lower than 2 mM in these body fluids analyzed ex vivo. Lysozyme was present in all analyzed body fluids, except sweat (data not shown and see Figure 3e ).
DISCUSSION
The eccrine sweat gland is one of the major cutaneous appendages with approximately 2-4 million glands that are distributed over nearly the entire body surface (Sato et al., 1989) . For long, only its role in thermoregulation was appreciated. Recently, DCD, a novel human AMP, was described as being a major constituent of eccrine sweat, thereby indicating that the eccrine apparatus is capable of functioning as an effector organ in the first line of defense of human skin. In our present investigation, we analyzed the proteolytic processing of DCD in eccrine sweat. Furthermore, we examined site-specific DCD expression as well as the kinetics of secretion and degradation of DCD peptides in eccrine sweat. Additionally, we addressed the question of whether other AMPs are present in significant amounts in human eccrine sweat. Using SELDI-TOF-MS analysis and RP-HPLC fractionation, we detected 14 DCD-derived peptides in eccrine sweat, 13 peptides of the C-terminus, and one peptide of the N-terminus of the full-length DCD sequence. Of the different truncated peptides, DCD-1L, DCD-1, SSL-46, LEK-45, LEK-44, LEK-43, and SSL-29 were found in at least two-thirds of all individuals. Our analysis revealed an average of seven different DCD-derived peptides (ranging from 4 to 10 DCD peptides) in eccrine sweat of healthy volunteers. Thus, by postsecretory proteolytic processing, the DCD gene product gives rise to a whole group of truncated DCD peptides with different biochemical properties and yet unknown functional activities.
DCD-1L and DCD-1 exhibit antimicrobial activity against Gram-positive organisms including S. aureus, E. faecalis, and Gram-negative organisms including E. coli (Schittek et al., 2001) . Further investigations revealed an extended antimicrobial spectrum including S. epidermidis (Vuong et al., 2004) , Pseudomonas putida, methicillin-resistant S. aureus, as well as rifampicin-and isoniazid-resistant Mycobacterium tuberculosis (Lai et al., 2005) . Additionally, shorter DCD fragments like SSL-46 (amino-acid positions 63-108) and SSL-25 exhibit antimicrobial activity (data not shown). Thus, analogous to the processing of other human AMPs like cathelicidin LL-37, proteolytically derived peptides exhibiting antimicrobial activity originate from the C-terminus of the full-length DCD peptide. Interestingly, proteolytically processed DCD peptides possess net charges between À2 and þ 2; thus, initially, anionic DCD-1L and DCD-1 are the source of the generation of neutral or cationic shorter DCD fragments due to subsequent processing. Whether the alteration from anionic to cationic peptides leads to a different antimicrobial spectrum and additional functional activities or is part of the inactivation of DCD peptides is subject to current investigations.
Proteolytic processing of DCD peptides and other sweatderived peptides and proteins may principally be due to host proteases, which can be keratinocyte-derived (Komatsu et al., 2003) or are produced by eccrine sweat glands. In eccrine sweat, diverse proteases have been described, among these kallikrein and kininase II (Fraki et al., 1970; Hibino et al., 1994) , acid proteases resembling cathepsin B1 and cathepsin D (Fraki, 1976) , and matrix metalloproteinase 19 (Sadowski et al., 2003) . Recent evidence suggests that the sweat-derived aspartate protease cathepsin D and a 1,10-phenanthroline sensitive carboxypeptidase (together with a yet unidentified endopeptidase) are involved in the postsecretory processing of DCD (Baechle et al., submitted). Furthermore, proteases derived from sebaceous glands may contribute to the degradation of AMPs on the skin surface (Frohlich et al., 1995; Komatsu et al., 2003) . It is noteworthy that the expression of the keratinocyte-derived matrix metalloproteinase 19 is upregulated under inflammatory conditions; therefore, the host is capable of modulating the proteolytic capacity on the outermost surface (Sadowski et al., 2003) . The sequence of full-length DCD is: MRFMTLLFLTALAGALVCAYDPEAASAPGSGNPCHEASAAQKENAGEDPGLARQAPKPRKQR SSLLEKGLDGAKKAV GGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL DCD-1L (amino-acid positions 63-110) is marked in bold, and the signal peptide (amino-acid positions 1-19) is marked in italics. Apart from host proteases, processing of DCD and potentially other AMPs in eccrine sweat may be due to microbialderived proteases. Recently, degradation of human cathelicidin LL-37 by the S. aureus-derived metalloproteinase aureolysin and the glutamylendopeptidase V8 protease was described (Sieprawska-Lupa et al., 2004) . Accordingly, P. aeruginosa elastase, E. faecalis gelatinase, or P. mirabilis metalloprotease are able to degrade and inactivate LL-37. Interestingly, besides antimicrobial DCD-derived peptides and proteases, which generate shortened DCD fragments, eccrine sweat additionally contains protease inhibitors such as cystatin A (Zeeuwen et al., 2001) . It is tempting to speculate whether these protease inhibitors play a role in the protection of proteolytic degradation of sweat-derived proteins and peptides by inhibition of either host-or microbial-derived proteases. Expression of a second AMP in eccrine sweat was described recently. The human cathelicidin LL-37 was detected by Western blot analysis in eccrine sweat in concentrations of 0.1 mM (Murakami et al., 2002) . In our investigation using SELDI-TOF-MS and RP-HPLC analysis followed by mass spectrometry and Edman sequencing, we could not detect the human cathelicidin LL-37, shortened LL-37-derivates, or the unprocessed precursor protein. Whereas Murakami et al. (2002 analyzed concentrated sweat (20:1 or 50:1) by Western blot analysis or RP-HPLC for the detection of LL-37 peptides, we used crude sweat samples for SELDI-TOF-MS analysis. To rule out a weak affinity of LL-37 to the reversed-phase chip, we analyzed synthetic LL-37 peptide spiked in sweat with the same protocol. Using this approach, synthetic LL-37 could clearly be detected in concentrations as low as 2 mM, the concentration required for antimicrobial activity of LL-37. The same experiments were performed for the a-and b-defensins, with similar results. As human a-and b-defensins and LL-37 are cationic peptides, we completed our experiments with the use of a cation exchange chip. Consistent with the results of the reversed-phase chip, none of these AMPs was detectable in eccrine sweat. Furthermore, we confirmed our results using Western blot analysis of human sweat for the a-and b-defensins and lysozyme. The data indicated that these peptides/proteins are either absent in eccrine sweat or present at amounts lower than 2 mM. In previous studies, expression of b-defensins HBD-1 and HBD-2 in eccrine sweat glands was described by in situ hybridization and immunohistochemistry (Fulton et al., 1997; Ali et al., 2001; Rieg et al., 2004) ; however, these peptides have not been identified in human sweat until now. In summary, we could not isolate other AMPs in several independent experiments and with different methods, and therefore conclude that in human sweat isolated ex vivo DCD-derived peptides are the main AMPs that are present in significant functional amounts.
Our results reveal a constant DCD secretion during 40 minutes of thermally induced sweating. This indicates a durable secretion of DCD in eccrine sweat, which is not subject to rapid exhaustion in periods of prolonged sweating. Additionally, we show that -despite further proteolytic processing generating shorter DCD derivates -DCD-derived peptides are still present 72 hours after incubation at room temperature. This indicates that DCD-derived peptides are relatively stable in sweat. Our findings are in accordance with previous reports of Sagawa et al., which managed to detect DCD-derived peptides by ELISA (for medicolegal aspects) in aged sweat for up to 11 weeks . Even in the absence of macroscopic sweating, a daily amount of B200 ml eccrine sweat is perspirated. Thus, a constitutive antimicrobial barrier overlying the epithelial sheets of the skin is secured by constant baseline DCD sweating, by durable DCD secretion when intense sweating occurs and by the continuous presence of DCD-derived peptides owing to proteolytic processing, which occurs with moderate to low kinetics. Site-specific expression of AMPs has been described for HBD-1 and HBD-2, with pronounced expression in plantar skin and in the scalp (Ali et al., 2001) . Accordingly, the newly described AMP psoriasin (S100A7) can be detected in highest concentrations on the skin surface of face, scalp, palms, and soles (Glaser et al., 2005) . We here demonstrate regional differences in the concentration of DCD-derived peptides in eccrine sweat with the highest amounts of DCD peptides in the sweat of palms, arms, and forehead. Taken together with the fact that the density of the eccrine sweat glands is highest at the palms, soles, and face, our results underline observations of site-specific expression of AMPs with pronounced DCD secretion in body areas, which are most often exposed to pathogens and minor trauma.
In conclusion, our results indicate that DCD is the predominant AMP expressed in eccrine sweat. Multiple DCD-derived peptides are generated by proteolytic processing, confirming the concept that human eccrine sweat represents a suitable and efficient vehicle to deliver innate defense molecules onto the skin surface. Through the continuous and abundant presence of DCD peptides in sweat, a constitutive first line of defense is established, which overlies the epithelial barrier of the skin.
MATERIALS AND METHODS
Collection of sweat, tears, saliva, and nasal secretions For SELDI-TOF-MS analysis of the proteolytic pattern of DCD peptides, eccrine sweat was collected from 18 healthy volunteers (seven women and 11 men, mean age 28.0 years, without skin or systemic diseases, who were on no systemic medications, except for two women on oral contraceptives, five volunteers were smokers) after sweat induction by physical exercise on a bicycle ergometer. For each participant, 5 ml of the initial portion of sweat of the forehead was collected and frozen immediately at À201C until analysis. Participants were asked not to wash or apply ointments 6 hours prior to the investigation. For the analysis of body sitespecific differences and DCD secretion over time, sweating was thermally induced by sauna visits. Of five healthy individuals (two women and three men, mean age 29.4 years), sweat samples were Sampling of tears was carried out with the help of sliced onions, and tears were also immediately frozen at À201C. The ethics committee of the medical faculty of Tü bingen University approved all described studies, and participants gave written, informed consent. The study was conducted according to the Declaration of Helsinki Principles.
Semiquantitative SELDI analysis of sweat, nasal secretions, tears, and saliva
The sweat samples were analyzed on a reversed-phase (H4) or a weak cation exchange (WCX2) Protein Chip Array (Ciphergen Biosystems, Freemont, CA). Sweat samples were centrifuged 1 minute at 13,000 r.p.m. (16,000 Â g) to remove particles or debris, but were not sterile filtered. For reversed-phase (H4) analysis, 1 ml of the supernatant was added to 4 ml 50 mM sodium phosphate buffer (pH 6.5). Protein Chip Arrays were pretreated with 3 ml of 50% (vol/ vol) acetonitrile/water for 1 minute, and after 2 minutes of drying, 1 ml of the diluted sweat solution was added. After drying (8 minutes), spots were washed four times with 3 ml H 2 O (by flushing each spot three times) and air-dried. For SELDI analysis with a weak cation exchange chip (WCX2), 1 ml of the supernatant was added to 4 ml of 50 mM sodium acetate, pH 4.0 (binding buffer). Protein Chip Arrays were equilibrated for 5 minutes with 3 ml of 50 mM sodium acetate (pH 4.0), and then the binding buffer was replaced by 1 ml of the diluted sweat sample. After 30 minutes of incubation in a humidity chamber, spots were washed three times with 3 ml of the binding buffer and once with 3 ml H 2 O, and air-dried. After drying 1 ml of matrix consisting of a saturated solution of sinapinic acid in 50% acetonitrile/water (vol/vol), 0.5% trifluoracetic acid with 100 fmol/ml bovine insulin (MW 5,733.6 Da) was added. SELDI-TOF-MS analysis of each sweat sample was performed in triplicate. Chips were read with the following instrument settings: laser intensity 230, detector sensitivity 8, detector voltage 19.7 kV, and positions 18-78 were read with an increment of 5, resulting in 12 different spot positions. Ten laser shots were collected on each position (total shots collected and averaged: 120/sample), and two warming shots were fired at each position, which were not included in the collection. The acquired mass range for the detection of DCD peptides included 0-12,500 Da with a focus mass at 4,800 Da. Furthermore, we performed several SELDI analyses from the respective samples in which we focused on different molecular weight ranges, from 0 to 12,500 Da with a focus mass at 4,800 or 10,000 Da and from 10-25 kDa with a focus mass at 19 kDa. Concentrating on molecular masses between 10 and 16 kDa, we detected lysozyme, using SELDI-TOF-MS in tears, nasal secretions, and saliva, but not in human sweat. Calibration was carried out with the bovine insulin peak (MW 5,733.6 Da). The spectra were analyzed by Protein Chip Software 3.1 (Ciphergen Biosystems, Freemont, CA). After baseline subtraction, all spectra were normalized to the internally obtained bovine insulin peak for semiquantification. We did provide evidence that the semiquantification of DCD peptides using SELDI-TOF-MS is adequate since the results are in accordance with the data we achieved with ELISA analysis of human sweat . Previous analyses revealed a high sensitivity of the SELDI-TOF-MS analysis with the detection of synthetic DCD-1 peptide by SELDI-TOF-MS in concentrations as low as 0.27 mM (Flad et al., 2002) . Samples of the other body fluids were analyzed accordingly, using the reversed-phase chip (H4).
HPLC analysis of eccrine sweat
Crude sweat was centrifuged 5 minutes at 13,000 r.p.m. (16,000 Â g). Eight hundred microliters of the supernatant was applied to an RP-HPLC on a Nucleosil C18 column (150 Â 10 mm) with 7 mm particles and a 100-Å pore size with a flow rate of 2.5 ml/ minute. Solvent A was 0.055% aqueous trifluoroacetic acid and . Stability of DCD-derived peptides in eccrine sweat. (a) Western blot analysis of eccrine human sweat after incubation periods of 0, 24, 48, and 72 hours at room temperature using the monoclonal antibody G-81, which recognizes C-terminal-derived DCD-peptides. DCD peptides were still detected in sweat after incubation of up to 72 hours at room temperature. Detection of human albumin (MW 67 kDa) was used as a loading control. (b) SELDI-TOF-MS analysis of native human sweat after incubation periods of 0, 4, 16, and 40 hours at room temperature using a reversed-phase (H4) protein chip. After baseline subtraction, spectra were normalized to the bovine insulin peak (5,733.6 Da). DCD peptides are still detectable after 40 hours of incubation at room temperature, yet a slow but continuous shift towards the processed DCD peptides LEK-43, LEK-42, LEK-41, and SSL-29 can be observed.
solvent B was 80% acetonitrile in 0.05% aqueous trifluoroacetic acid. A linear gradient of 5% B to 80% B over 40 minutes was used.
The resulting elution peaks were collected and lyophilized. DCDderived peptides were identified by matrix-assisted laser desorption ioni- . Spectra of SELDI-TOF-MS analysis of (a) tears, (b) nasal fluid, and (c) saliva from three healthy volunteers. The a-defensins HNP-1 (3,442.1 Da), HNP-2 (3,371.0 Da), and HNP-3 (3,486.1 Da) are marked in a box. Shown are masses from 2,000 to 6,000 Da. After baseline subtraction, spectra were normalized to the bovine insulin peak (5,733.6 Da).
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